The observed improvements in liver TG levels, gene expression related to mitochondrial biogenesis, and the expression of critical regulators such as SIRT1, TFAM, and PGC1-α highlight the potential of these compounds in combating NAFLD and promoting mitochondrial health. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.